We are assembling a dynamic team who are passionate about realising the potential of the ground-breaking SINEUP® technology.
Jan has more than 20 years’ experience of building and leading cross functional teams to drive delivery of innovative technologies. He has built platforms and played a leadership role in the commercialisation of multiple therapeutics across small molecule, biopharmaceutical and gene therapy modalities. Jan joined Transine Therapeutics from Freeline Therapeutics where he was start-up CEO then Chief Development Officer during a 5 year period from company start up through to successful IPO, overseeing deployment of a novel AAV platform and a rapidly growing clinical-phase portfolio. Prior to this Jan spent close to 20 years at GSK in multiple roles spanning from Discovery to Manufacturing environments, including senior leadership roles in the rapidly growing Biopharma business. Latterly, Jan oversaw the establishment of the Cell & Gene Therapy platform unit and played a pivotal role in the commercialisation of Strimvelis, the first ex-vivo gene therapy to receive an EU Marketing Authorisation Application. He has served on multiple advisory boards in the CMC and regulatory space, playing a significant role in the shaping of the Cell and Gene therapy field. Jan holds an MA in Chemistry and a PhD in Biological Chemistry from Oxford University.
Sinem recently obtained her Ph.D in Cell Biology from the School of Pharmacy, University of East Anglia. Her focus before joining Transine has been on investigating the molecular mechanism of action of a broad range of natural and pharmaceutical compounds in immune cells. Sinem brings expertise and comprehensive skills in cell culture, cell-based assays, biochemistry and molecular biology techniques and an in-depth knowledge of cells signalling pathways.
Mathieu has long-standing experience in characterising RNA/DNA regulatory networks underlying cell function, identity and plasticity. He joins Transine from the MRC - London Institute of Medical Sciences where he was Group Leader of a team focused on understanding how the dysfunction of non-coding RNA circuits underlie stress-mediated dysfunction in disease. Mathieu used state-of-the-art multi-omics technologies coupled to a repertoire of in vitro and in vivo to develop innovative antisense therapy improving patient health. Mathieu was an Honorary Senior Lecturer at Imperial College London and holds a PhD in Experimental Medicine from McGill University.
Sarah joins Transine Therapeutics after co-leading the seed-funding of the company as a Partner in TVI. Sarah has over 15 years’ experience in preclinical research in both UK and USA-based organisations. With a specialist interest in Neuroscience research, Sarah has held a number of senior management positions within big pharma, and junior faculty and visiting Professorship positions in academia. Over the course of her career, Sarah has established high calibre multidisciplinary teams and strategic academic collaborations. Sarah holds a PhD in Pharmacology from the University of Cambridge.
Cintia joins Transine Therapeutics from Takeda Ventures, having worked in senior level executive support for over 10 years. Previously working for blue chip companies including Loreal, Pfizer and Unilever, Cintia’s experience ranges from high level executive support to office management, procurement and operations. Cintia has a bachelor’s degree in business and Administration from San Francisco University Sao Paulo, Brazil.
Emmanuelle joins the team from the Wellcome Sanger Institute and brings with her 15 years’ experience in sourcing, managing, developing, and partnering IP. Emmanuelle has significant business development experience in forging industrial collaboration around innovation and in commercialisation of genomic research, for which she was named one of the Movers and Shakers of BioBusiness 2020. Emmanuelle holds a PhD in Immunology from the Pasteur Institute, Paris.
Madeleine joins Transine Therapeutics with over 20 years’ experience in biopharmaceutical research and development, and programme and portfolio management. Previously working for BioVex, GSK, MedImmune, MRC, Autolus, Crescendo and Cellinta, Madeleine has held increasingly senior programme management positions with vast experience in building and leading high performing matrix teams from discovery to clinical stage. Alongside programme management, Madeleine also brings significant alliance and operational management experience to Transine. Madeleine holds a PhD in Molecular Virology from the University of Edinburgh and is PMP® certified.
An expert cell biologist, Marc has over 18 years’ worth of experience in CNS biology and in vitro cell models. During this time, he has worked in academic, biotech and global pharmaceutical environments and has significant leadership experience focused on discovery projects ranging from pre-clinical to candidate selection stages. With experience in small molecules and biologics, Marc has significant collaborative experience with external partners, delivery key project data from CROs and academic labs. Marc holds a PhD in Neuroscience from the University of Manchester.
Ana is a highly proficient cell biologist with 10 years’ experience working in biotech, being integral to driving and executing laboratory activities both in early stage and lead projects up to candidate selection stages. Before joining the team, Ana worked at Mission Therapeutics where she led in vitro and in vivo work packages to enable clinical development of small molecule inhibitors targeting mitochondrial dysfunction. Ana has significant research experience in a range of therapeutic areas including Oncology and Neuroscience. Ana holds a PhD in Developmental Biology from the University of Sheffield.
Laura joins the team from Cell Guidance Systems, where she deployed her significant research capabilities to develop key assays for SINEUP evaluation. With a strong background in Neuroscience, Laura undertook a Postdoctoral Fellowship at the MRC Laboratory of Molecular Biology, Cambridge. Laura has extensive experience in specialized tissue culture, together with an impressive track record in the detailed characterization of in vivo model of CNS disease. Laura gained her PhD in Cellular and Molecular Biology from the University of Dundee.
Kinga is a highly skilled molecular biologist with over 10 years’ experience working in biotech developing platform technologies. Before joining the Transine team, Kinga led the in vitro development of dbDNA™ based therapeutics at Touchlight Genetics, including candidates for progression in vaccine trials. Kinga also has extensive experience of vector and process development for cell reprogramming and production of monoclonal antibodies, AAV or Lentivirus.